165 related articles for article (PubMed ID: 16228631)
1. Factors that influence prescribers in their selection and use of COX-2 selective inhibitors as opposed to non-selective NSAIDs.
Gunnarsdóttir AI; Kinnear M
Pharm World Sci; 2005 Aug; 27(4):316-20. PubMed ID: 16228631
[TBL] [Abstract][Full Text] [Related]
2. Concomitant use of gastroprotective drugs among elderly NSAID/COX-2 selective inhibitor users: a nationwide register-based study.
Johnell K; Fastbom J
Clin Drug Investig; 2008; 28(11):687-95. PubMed ID: 18840011
[TBL] [Abstract][Full Text] [Related]
3. "Selective" switching from non-selective to selective non-steroidal anti-inflammatory drugs.
Bennett K; Teeling M; Feely J
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):645-9. PubMed ID: 12942226
[TBL] [Abstract][Full Text] [Related]
4. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
Hsiang KW; Chen TS; Lin HY; Luo JC; Lu CL; Lin HC; Lee KC; Chang FY; Lee SD
Clin Ther; 2010 Jul; 32(7):1294-303. PubMed ID: 20678677
[TBL] [Abstract][Full Text] [Related]
5. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
Arellano FM; Yood MU; Wentworth CE; Oliveria SA; Rivero E; Verma A; Rothman KJ
Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of rational nonsteroidal anti-inflammatory drugs and gastro-protective agents use; association rule data mining using outpatient prescription patterns.
Pattanaprateep O; McEvoy M; Attia J; Thakkinstian A
BMC Med Inform Decis Mak; 2017 Jul; 17(1):96. PubMed ID: 28676124
[TBL] [Abstract][Full Text] [Related]
7. Long-term NSAID use in primary care: changes over a decade and NICE risk factors for gastrointestinal adverse events.
Thompson PW; Tee L; McBride J; Quincey D; Strat Liddiard G
Rheumatology (Oxford); 2005 Oct; 44(10):1308-10. PubMed ID: 15972345
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ; Islam K
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
[TBL] [Abstract][Full Text] [Related]
9. Motivations and perceived influences on rural and urban general practitioners when prescribing conventional non-steroidal anti-inflammatory drugs or COX-2 inhibitors.
Behan K; Cutts C; Tett SE
J Clin Pharm Ther; 2005 Aug; 30(4):337-43. PubMed ID: 15985047
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
11. [Can COX-2 selective inhibitor prevent NSAIDs-related GI toxicity?].
Konishi H; Yoshikawa T
Nihon Rinsho; 2011 Jun; 69(6):1110-5. PubMed ID: 21688637
[TBL] [Abstract][Full Text] [Related]
12. Study of usage pattern of nonsteroidal anti-inflammatory drugs (NSAIDs) among different practice categories in Indian clinical setting.
Paul AD; Chauhan CK
Eur J Clin Pharmacol; 2005 Feb; 60(12):889-92. PubMed ID: 15605276
[TBL] [Abstract][Full Text] [Related]
13. GP and patient perspectives on treatment with non-steroidal anti-inflammatory drugs for the treatment of pain in osteoarthritis.
Crichton B; Green M
Curr Med Res Opin; 2002; 18(2):92-6. PubMed ID: 12017216
[TBL] [Abstract][Full Text] [Related]
14. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract.
Sostres C; Gargallo CJ; Arroyo MT; Lanas A
Best Pract Res Clin Gastroenterol; 2010 Apr; 24(2):121-32. PubMed ID: 20227026
[TBL] [Abstract][Full Text] [Related]
16. Possible link between history of hypersensitivity to a specific non-steroidal anti-inflammatory drug (NSAID) and positive results following challenge test to alternative NSAIDS.
Trombetta D; Imbesi S; Vita G; Isola S; Minciullo PL; Saija A; Gangemi S
Arzneimittelforschung; 2009; 59(8):410-4. PubMed ID: 19813464
[TBL] [Abstract][Full Text] [Related]
17. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
18. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
Joshua FF; Oakley SP; Major GA
Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
[TBL] [Abstract][Full Text] [Related]
19. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
Strand V
Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
[TBL] [Abstract][Full Text] [Related]
20. Changing perceptions and practices regarding aspirin, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs among US primary care providers.
Elnachef N; Scheiman JM; Fendrick AM; Howden CW; Chey WD
Aliment Pharmacol Ther; 2008 Nov; 28(10):1249-58. PubMed ID: 18729848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
